Biolegend, 596955, Biotinylated Recombinant Human SIRPG (carrier-free), 50μg

SIRPG or SIRP-gamma or SIRPγ (signal-regulatory protein γ) is a receptor protein involved in the negative regulation of receptor tyrosine kinase coupled signaling processes. It has been suggested that SIRPG signaling may play an immunoregulatory role in maintaining peripheral immune tolerance and preventing autoimmunity. SIRPG which has the same ligand that is, CD47 as SIRPα, expressed on T cells and activated NK cells. SIRPG-CD47 interaction mediates cell-cell adhesion and supports APC-T cell contact, enhancing antigen presentation, the consequent T cell proliferation and cytokine secretion. It seems unlikely that SIRPG itself generates intracellular signals because it does not have any recognizable signaling motifs. Instead, SIRPG may trigger signaling of CD47 in APCs. Although SIRPG is the only member of the SIRP family with known T1D (type I diabetes) risk loci, other proteins found in this family, such as SIRPα and SIRPβ1, may also be involved in ‘Type 1 Diabetes’ pathogenesis. The high expression of SIRPG is significantly associated with both T1D and LP (Lichen planus, a common chronic inflammatory skin disease) and this upregulation of SIRPG may exacerbate disease progression by regulating immune responses, promoting inflammation and causing tissue damage.
50μg
Source: Human SIRPG, amino acids Glu29-Pro360 (Accession # Q9P1W8.3), with a C-terminal 6xHis tag and an Avi tag was expressed in CHO cells.
Molecular Mass: The 353 amino acid recombinant protein has a predicted molecular mass of approximately 39.4 kD. The protein migrates approximately at 40-50 kD in SDS-PAGE in DTT-reducing and non-reducing conditions.
N-terminalSequence Analysis: The predicted N-terminal amino acid is Glu.
Purity: > 95%, as determined by Coomassie stained SDS-PAGE.
Formulation: Lyophilized from 0.22 µm filtered protein solution in PBS, pH 7.2 with 5% trehalose.
Endotoxin Level: Less than 0.1 EU per μg of protein as determined by the LAL method
Concentration: 50 µg size, Lyophilized
Storage & Handling: Unopened vial can be stored between 2°C -4°C for up to two weeks and at -20°C or colder until the expiration date. Reconstitute lyophilized protein in sterile water preferably in sterile deionized water. Before reconstitution, make sure sterile water and the product are at room temperature. Quickly spin the vial or gently tap down on the vial to make sure the lyophilized product is at the bottom of the vial before opening. Use aseptic techniques to add the required volume of reconstitution buffer (sterile water) to the vial, to obtain the recommended stock concentration 250 μg/mL. Close the vial and leave at an ambient temperature for 15-20 minutes. Then gently invert the vial several times or until all the lyophilized product dissolves. Leave the vial at room temperature for another 15 minutes. If small particulates are still observed after 15 minutes, incubate at room temperature for an additional 30 minutes and leave the vial at 2°C - 8°C overnight. Next day, invert the vial several times or gently pipette the solution up and down before use. If needed, transfer the reconstituted stock solution to a sterile container for additional dilution to no less than 100 μg/mL. Small working aliquots in polypropylene tubes can be made after reconstitution and store the vials at -20°C or lower. Avoid freeze/thaw cycles. Carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to two weeks or stored at -20°C or colder for up to 3 months.
Activity: Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
Application: Bioassay
Application Notes: Our lyophilized proteins are validated in-house to maintain activity after shipping at ambient temperature and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Structure: Monomer
Distribution: CD4+ T-cells, CD8+ T-cells, CD56-bright natural killer (NK) cells, CD20+ cells, and all activated NK cells
Function: T cell and NK cell activation, cell-cell adhesion, supports APC-T cell contact, enhance antigen presentation, T cell proliferation and cytokine secretion
Interaction: CD47 expressing cells
Ligand/Receptor: CD47
Bioactivity: Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
Cell Type: Antigen-presenting cells, Granulocytes, Monocytes
Molecular Family: CD Molecules
Antigen References: Sharp RC, et al. 2021. Frontier Immunology. 12:739048. Ichigotani Y, et al. 2000. J. Hum. Genet. 45:378. Nettleship JE, et al. 2013. Crystal BMC Struct. Biol. 13:13. Sinha S, et al. 2018. Sci. Rep. 8:15440. Sinha S, et al. 2019. Clin. Immunol. 198:57. Sharp RC, et al. 2021. Front Immunol. 12:739048. Brooke G, et al. 2004. J. Immunol. 173: 2562. Piccio L, et al. 2005. Blood. 105:2421. Van Beek EM, et al. 2005. J. Immunol. 175: 7781. Wu Ji, et al. 2024. Medicine (Baltimore). 103:e40454.
Gene ID: 55423
UniProt: View information about SIRPG on UniProt.org
Regulatory Status: RUO
Other Names: CD172g, SIRPB2, SIRP-B2, bA77C3.1, SIRPgamma